Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

ide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. In March 2007, the FDA granted marketing approval for the Company's first product, Soliris for all patients with PNH and the Company began commercial sale of Soliris in the U.S. during April 2007. In June 2007, the European Commission granted marketing approval for Soliris in the European Union for all patients with PNH. The Company is evaluating other potential indications for Soliris as well as other formulations of eculizumab for additional clinical indications, and is actively pursuing development of other antibody product candidates in early stages of development. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at: http://www.alexionpharm.com.

This news release contains forward-looking statements, including statements related to potential benefits and commercial potential for Soliris, and interest about Soliris in the patient, physician and payor communities. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capability and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties won't agree to license any necessary intellectual property to us on reasonable terms or at all, the risk that third party payors will not reimburse for the use of Soliris at acceptable rates or
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015 HeartWare International, Inc . ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... President and Chief Executive Officer, Doug Godshall , ... Annual Growth Conference at 8:30 a.m. EDT on Thursday, ... 12-13, 2015 at the InterContinental Boston. A ...
(Date:8/4/2015)... Levi & Korsinsky is investigating the Board ... (NASDAQGS: BIIB) for possible violations of federal securities laws. ... officers and/or directors have violated Sections 10(b) and 20(a) ... July 24, 2015, prior to the opening of the ... Among other things, the Company lowered its prior revenue ...
(Date:8/4/2015)... Pharmaceuticals, Inc. (Nasdaq: ISIS ) today reported net ... three and six months ended June 30, 2015, respectively, ... $43.4 million for the same periods in 2014. Isis, ... more than $90 million of revenue Isis earned in ... Bayer to license  ISIS-FXI Rx .  Isis increased its ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Biogen Inc. and Its Board of Directors in Connection with Possible Violations of Federal Securities Laws -- BIIB 2Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16
... ALLEGAN, Mich., May 10, 2011 Perrigo Company (Nasdaq: ... to settle all Hatch-Waxman litigation relating to fluticasone lotion brought ... relevant patents. Under the terms of the settlement, Perrigo can ... 22, 2012, or earlier under certain circumstances. ...
... Tenn., May 10, 2011 MedQuist Holdings Inc. (NASDAQ: ... transcription services and technology-enabled clinical documentation workflow solutions, today ... St. Joseph,s Hospital Health Center in Syracuse, New York, ... projected to achieve significant cost savings and improve efficiency ...
Cached Medicine Technology:Perrigo Announces Settlement of Cutivate Lotion Litigation 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 2MedQuist Awarded Clinical Documentation Outsource Contract for St. Joseph's Hospital Health Center With Focus on Cost Savings, Quality, Peace of Mind 3
(Date:8/4/2015)... ... ... assistPoint Partners, LLC is proud to announce a ... Through a secure web portal, assistPoint connects Life Sciences, Patients and Providers together ... and workflow solution. This provides cancer center patient advocates, financial counselors and business ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Healthy Origins® Cognizin® is a trademark for Citicoline, a nutrient that supports ... capsule for those applications which have more of a semi-solid composition. Vegetarian ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA is ... non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in the ...
(Date:8/4/2015)... ... August 04, 2015 , ... Recent studies in ... rise in binge drinking among certain populations and specific locations. Researchers, ... to examine trends and evidence to help facilitate health care treatment to meet ...
(Date:8/4/2015)... ... August 04, 2015 , ... They say a picture is worth a thousand ... and medical art can be essential. StayWell, a health solutions company, announced today it ... solutions have been used by physicians and other health care providers for more than ...
Breaking Medicine News(10 mins):Health News:assistPoint.com Web Site Launched 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3
... April 18 An ex-White house aide,Robert Weiner, and ... cancer lab, are reporting that many scientists believe that ... a drop in real dollars for,cancer research, and private ... of the federal government." Discoveries are being,lost due to ...
... Coyote goes,hungry in cartoon land, it,s because Roadrunner ... Food Bank wins when nobody goes hungry., ... ), In that spirit, strategic communications firm ... to highlight the tragedy of hunger in New,Mexico ...
... showing the cancer may have an Achilles, heel, report suggests ... Gleevec has forced metastatic melanoma into remission for the first ... , The case involves a 79-year-old woman with melanoma tumors ... an abnormality in a gene called KIT, so the patient ...
... Family Research Council,Action applauds GOP Presidential candidate ... Villanova University supporting the pro-life,platform of the Republican ... of possible running mates., FRC Action,s Senior ... hear Senator McCain depict his support for life ...
... TSTF ), a national provider of healthcare and administrative,staffing ... of Shareholders held on April 17, 2008, at the ... annual meeting, shareholders approved the election of Rick J.,Filippelli ... Directors. In,addition, the Company,s shareholders also approved a proposal ...
... drugs had sharper declines in thinking skills, study finds ... known as anticholinergic drugs -- used to treat ulcers, ... -- may cause older people to lose their thinking ... medicines, new research suggests. , "What we found is ...
Cached Medicine News:Health News:Reduced Funds for Cancer is Cost of Iraq, Say Ex-White House Aide, Cancer Researchers 2Health News:BEEP BEEP!! Strategic Communications Firm DW Turner Thwarts Hunger in Partnership With Roadrunner Food Bank 2Health News:Gleevec Pushes Advanced Melanoma Into Remission 2Health News:FRC Action Praises John McCain's Pro-Life Comments 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 2Health News:TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders 3Health News:Common Medications May Harm Memory in Older People 2Health News:Common Medications May Harm Memory in Older People 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: